On 17 November 2026, the Federal Circuit ruled in Cocona v VF Outdoor that claims reciting a moisture vapour transmission rate (MVTR) range are invalid as indefinite. The patent described more than one way to measure MVTR but never said which one decides infringement.
The decision affirms a judgment for VF Outdoor, owner of The North Face brand, and Columbia Sportswear. It matters to anyone who claims a material by a measured property, because a number in a claim is only as definite as the test behind it.
What happened
Cocona owns US Patent 8,945,287 on a waterproof, breathable membrane containing active particles such as activated carbon. Asserted claims 1, 38 and 39 each require an MVTR of about 600 to about 11,000 g/m²/day.
The specification offers a choice of tests without a rule for choosing. It lists upright and inverted cup methods, and possibly a third (the parties disputed whether Mocon is a separate method). Its single example uses optional wording and points to the ASTM International E96-94 water method, a standard that itself allows a range of temperatures and humidity levels.
The decisive point was that the method changed the answer. In a provisional application incorporated into the patent, one sample measured 223 g/m²/day upright, outside the range, and 1,394 g/m²/day inverted, inside it. A control sample in the patent showed the same split.
Judge Christine Arguello of the District of Colorado held the claims indefinite. Writing for a panel with Judges Lourie and Stoll, Judge Stark affirmed under the reasonable certainty test the Supreme Court set in 2014. Following Dow v Nova and Teva v Sandoz, the court held that several methods giving different results, without guidance on which to use, leave claim scope uncertain.
The court added two limits. Naming more than one method is not fatal in itself. Data from a sample can show uncertainty even if that sample does not practise every claim element.
Not the first claim to fail for want of a single method
A year earlier, on 25 November 2025, the court applied the same principle to software. In Akamai v MediaPointe, claims to “optimal” and “best” routes for streamed media were held indefinite. The claims relied partly on trace-route results, but the patent gave no guidance on whether hops, latency or reliability governed when they diverged.
Europe shows the reverse side of the issue. On 23 October 2026, the Unified Patent Court (UPC) Mannheim Local Division dismissed SK nexilis’ action against Volta Energy Solutions over copper foil patent EP 3 316 363. The claim counted surface peaks per 4 mm sampling length, and the court applied that definition rather than the 1 cm basis SK nexilis said the industry uses. On a 4 mm count, the accused foil fell below the claimed range.
Synoptic IP’s analysis of the SK nexilis copper foil decision covers the case in more detail. Together, the two cases show the cost of loose drafting in both directions: an open method risks indefiniteness, while a precise one can bind the patentee.
The wider picture on claims and the specification
The Federal Circuit does not strike down every flexible term. On 12 January 2023, in Grace Instrument v Chandler Instruments, it vacated a finding that “enlarged chamber” in a viscometer patent was indefinite. The specification and prosecution history explained what the chamber had to do, which gave enough of a boundary to send the case back.
The Supreme Court applied comparable logic to breadth in Amgen v Sanofi, decided unanimously on 18 May 2023. Functional antibody claims failed for lack of enablement, and Justice Gorsuch wrote that “the more one claims, the more one must enable.”
At the European Patent Office (EPO), the Enlarged Board of Appeal ruled in G 1/24 on 18 June 2025 that the description and drawings must always be consulted when interpreting claims for patentability.
These decisions point the same way. The specification is increasingly treated as the measure of claim scope, and gaps the patentee could have filled count against the patent.
What it means for applicants and implementers in materials and chemistry
For applicants, a claimed parameter is safest when tied to one stated test method, with conditions, sample preparation and units. Optional wording such as “may be measured” has now proved costly where the method changes the result. Data in priority documents deserve the same review, because incorporated material can be used against the claims.
For implementers, the reasoning offers an invalidity route. A focused invalidity search can compare the patent’s methods, the cited standards and its own examples for results that diverge. Freedom-to-operate reviews can also test a planned product under each disclosed method, since the outcome may differ.
For portfolio owners, older parameter claims drafted without a fixed method carry the risk that Dow and Teva had already created.
Synoptic IP’s view
Synoptic IP’s view is that Cocona applies settled law rather than creating new law, but it states the rule with unusual clarity. The court relied on its earlier multiple-methods decisions, the same line Akamai applied in 2025. The facts were stark: several methods, optional language and conflicting results in the patent’s own documents.
The lesson concerns drafting discipline. Grace shows that a specification which explains a term can save it. Cocona shows that a specification offering choices, without a rule for choosing, cannot. SK nexilis adds that a precise definition can bind the patentee abroad, so the method chosen should match how products are actually tested.
The strongest counter-argument is that the claimed range was very wide. None of the seven active-particle samples in the patent’s main data table fell inside the range under one method and outside it under the other. On that view, the uncertainty was largely theoretical.
The view still holds because the court accepted that such data can reveal uncertain scope, and the patent gave competitors no way to resolve it. Where a patent points to a single established method, as in earlier cases the court distinguished, the result may differ.
If you are drafting parameter claims or testing their validity, our patent drafting and invalidity search teams can help.
This article is commentary and opinion based on public reports as of 20 November 2026 and is not legal advice.